Retacrit (Epoetin Alfa-EPBX, Biosimilar to Epogen) 10,000 Units/mL

$1,375.00

Chronic Kidney Disease-Associated Anemia
– Reduction of need for red blood cell (RBC) transfusion in patients with chronic kidney disease (CKD) on dialysis and not on dialysis
CKD on Dialysis
– Initiate treatment when hemoglobin (Hgb) level <10 g/dL
– If Hgb level approaches or >11 g/dL, reduce or interrupt dose
– 50-100 units/kg IV/SC 3 times weekly initially
CKD NOT on Dialysis
– Initiating treatment only when Hbg level is <10 g/dL and the following:
– Rate of Hgb decline indicates the likelihood of requiring a RBC transfusion
– Reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal
– If Hgb level >10 g/dL, reduce or interrupt dose, and use the lowest dose of epoetin alfa sufficient to reduce the need for RBC transfusions
– 50-100 units/kg IV 3 times weekly initially
 
Chemotherapy-Related Anemia
– Treatment of anemia in patients with non-myeloid malignancies where anemia is due to effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of 2 additional months of planned chemotherapy
– Initial Dose: 150 units/kg IV/SC 3 times weekly
– 40,000 units SC once weekly until completion of chemotherapy course
– Rx Required
– Accept FSA & HSA Cards
– Free Overnight Shipping (CA)
– No Shipping to Outside of California
NDC: 00069-1308-10 Category:

10 Vials = 1 Unit

Description

Drug Info: ApoThera Drug Disease Clinical Support App

– SC is the preferred route of administration except in patients with CKD on hemodialysis
– In patients with CKD on hemodialysis, the IV route is recommended.
– Do not shake
– Epoetin is usually administered undiluted, although preservative-free (single-dose vial) formulations may be diluted in a syringe prior to administration as a 1:1 dilution using bacteriostatic NS
Storage
– Vials should be stored at 2°C to 8°C (36°F to 46°F)
– Do not freeze
– Do not shake
– Protect from light
Single-Dose Vials (SDV)
– Single-dose 1 mL vial contains no preservative.
– Use one dose per vial
– Do not re-enter vial; discard unused portions.
– Single-dose vials (except 40,000 units/mL vial) are stable for 2 weeks at room temperature.
– Single-dose 40,000 units/mL vial is stable for 1 week at room temperature
Monitoring
– Transferrin saturation and serum ferritin (prior to and during treatment)
– Hemoglobin (weekly after initiation and following dose adjustments until stable and sufficient to minimize need for RBC transfusion, CKD patients should be also be monitored at least monthly following hemoglobin stability)
– Blood pressure
– Monitor for signs of seizures (CKD patients following initiation for first few months, includes new-onset or change in seizure frequency or premonitory symptoms)
Tags: , , , , , , , , , , , , , , , , , , ,

Related Products